M&A, People

‘Most feared’ activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout?

The “most feared man in corporate America” has just set his sights on Bristol-Myers Squibb. And that may make some of Bristol-Myers more than a little uncomfortable this morning as they continue to push their controversial $74 billion Celgene buyout.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 42,100+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->